SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is in the spotlight as investors react to a record revenue report and raised full-year guidance, with the community actively debating whether the earnings reaction is a short-term shakeout or a sign of long-term growth. The high short interest has fueled significant discussion around the potential for a short squeeze as shareholders weigh the company's aggressive investment phase and expanding drone technology backlog against the EPS miss.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is experiencing significant volatility as investors debate the impact of delayed mission timelines against a massive, rapidly expanding backlog. The community remains sharply divided, with some traders viewing the current price as a deep-value buying opportunity while others express skepticism regarding execution, potential dilution, and persistent earnings misses.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending following the delivery of its Horizon 1 AI data center to Microsoft and the achievement of NVIDIA Exemplar Cloud status, fueling strong investor optimism. The community is actively debating the stock's potential for a short squeeze, citing high institutional ownership and substantial short interest as key drivers for a potential run toward the $50 level.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors focus on the company's progress toward a Q4 2026 BLA submission for its prostate cancer therapy, alongside optimism surrounding its upcoming presentation at the August Canaccord Genuity Growth Conference. The community is actively debating the significance of recent institutional accumulation and manufacturing milestones, while weighing the potential impact of competitive oncology developments on the company's valuation.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco Systems is currently trading in the spotlight as investors digest recent double-beat quarterly results and updated long-term guidance driven by a "networking supercycle." While shares experienced significant volatility following the report, the community remains actively divided between those betting on long-term AI infrastructure growth and those concerned that the stock's recent rally left little room for immediate upside.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors digest the impact of the DaVita contract, which is being viewed as a significant operational milestone for the long-term adoption of DefenCath. While sentiment remains strongly bullish due to the contract news and recent financial updates, message boards are actively debating the company's future guidance and the ongoing influence of institutional positioning versus retail sentiment.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is trending as investors digest strong sector read-throughs from peers and a price target raise from Goldman Sachs, which highlights robust artificial intelligence server demand. The community is actively debating the company's valuation metrics and backlog health, with bulls pointing to fundamental AI infrastructure growth while some traders remain cautious about recent price volatility.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is currently a focal point for investors as the community anticipates major technical updates and potential government contract announcements following a recent earnings report. Shareholders are actively debating the company's valuation compared to sector peers and expressing strong conviction in its long-term potential, despite concerns from some over market volatility and short-term price fluctuations.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is experiencing significant market volatility as investors weigh the company's recent earnings results against aggressive long-term revenue growth guidance and the impending impact of share lockup expirations. While some community members are capitalizing on the rapid price swings, others remain skeptical about the firm's valuation, leading to an active debate between those betting on long-term institutional adoption and those expecting further downside pressure.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is seeing extremely high social volume and bullish sentiment as traders focus on a potential short squeeze, fueled by a strong Q2 earnings beat and anticipation of a price-to-sales valuation re-rating. While many community members are celebrating the company's profitability and pipeline, some voices urge caution, noting that the crowd's enthusiasm and volatility may be outstripping the underlying news.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?

Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.

Dyne Therapeutics Stock Tumbles After Hours: Here's Why

Dyne Therapeutics stock fell after hours after pricing an upsized $375M public offering of common stock.read more...

Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock

Equity

Dyne Therapeutics announced plans to raise $300 million through a public stock offering on Tuesday.


SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space

Citi reiterated a ‘Sell’ rating on SRPT, citing the expected rise in competition within the Duchenne muscular dystrophy (DMD) exon-skipping market.


DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?

Dyne gains momentum as FDA priority review for its lead DMD therapy and progress in its DM1 program strengthen confidence in its pipeline.

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026...

Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?

Key PointsDyne Therapeutics focuses on high-potential therapies for rare neuromuscular diseases using its proprietary FORCE platform...

Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsDyne Therapeutics is leveraging its FORCE platform to target rare neuromuscular diseases with high unmet need...

Dyne Therapeutics (DYN) Reaches Key Regulatory Milestone

Dyne Therapeutics (DYN) Reaches Key Regulatory Milestone...

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean

Key PointsFCPM III sold 818,460 shares of Dyne Therapeutics last quarter; the estimated transaction value was $14.11 million based on average prices...

Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Dyne Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

DYNDyne Therapeutics Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest DYN News